Where Will Innoviva Inc (INVA) Stock Go Next After It Is Down 0.61% in a Week?

The market has been down on Innoviva Inc (INVA) stock recently. INVA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Innoviva Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on INVA!

See Full INVA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With INVA Stock Today?

Innoviva Inc (INVA) stock is higher by 0.2% while the S&P 500 has fallen -0.73% as of 1:26 PM on Friday, Mar 15. INVA is higher by $0.03 from the previous closing price of $14.72 on volume of 332,008 shares. Over the past year the S&P 500 is higher by 31.37% while INVA is higher by 29.05%. INVA earned $2.07 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.13. To screen for more stocks like Innoviva Inc click here.

More About Innoviva Inc

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Click Here to get the full Stock Report for Innoviva Inc stock.